Dr. Jason Mark Beckta, MD, PhD

Dr. Beckta practices at Rutland Regional Medical Center in Rutland, Vermont, part of River Region Human Services.

Dr. Beckta's NPI, 1295182442, was assigned on May 18, 2016. Dr. Beckta graduated from Virginia Commonwealth University School of Medicine in 2016. Dr. Beckta holds Vermont license 042-0016454.

Dr. Beckta's primary practice is Rutland Regional Medical Center, at 160 Allen St, Rutland, VT 05701 in Rutland County. The practice phone is (802) 775-7111.

Dr. Beckta's primary practice is Rutland Regional Medical Center in Rutland, Vermont, part of River Region Human Services. Dr. Beckta is also affiliated with Dartmouth Hitchcock Medical Center. The medical group on file is University of Vermont Medical Center. Dmand AI also links Dr. Beckta to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Beckta practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Beckta's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Beckta's licenses on file in 2 states: Vermont and New York.

CMS data shows 2,892 Medicare services from Dr. Beckta across 17 procedure codes in 2024, for 229 Medicare patients. Medicare paid $199,395 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 229 Medicare patients who saw Dr. Beckta in 2024. The largest group is 65 to 74, with 110 patients. 75% of them have cancer, and 63% have high blood pressure. 18% are also on Medicaid. Their average risk score is 1.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Beckta's median patient age at 73, with 40% women.

In 2024, Dr. Beckta wrote 101 Medicare Part D claims for 48 patients. 92% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $240 in total drug cost. In 2022, CMS named 35 claims across 2 drugs.

Dr. Beckta accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 31 papers to Dr. Beckta, published from 2012 to 2024. 2020 was the busiest year, with 6. The most frequent topics are Ataxia Telangiectasia Mutated Proteins, Brain Neoplasms and Cell Line, Tumor. Dr. Beckta has published most often in Pract Radiat Oncol. Dr. Beckta's most frequent co-authors are Ranjit S. Bindra, MD, PhD, Christopher Sungwoon Hong, MD and Aladine Abdalla Elsamadicy, MD.

CMS Open Payments shows 1 general payment to Dr. Beckta from 1 drug or device company in 2021. Food and beverage make up the largest share, 100% of the total. icotec Medical Inc. paid the most, $156.

Dr. Beckta graduated from Virginia Commonwealth University School of Medicine in 2016.